Nektar Therapeutics reported encouraging Phase 2b data for rezpegaldesleukin (rezpeg), an immune-modulating agent showing statistically significant improvement in skin clearance for patients with atopic dermatitis. Despite the trial data not reaching benchmarks set by competing products such as Dupixent, the positive outcomes ignited investor enthusiasm, doubling the company’s stock price. This success signals a potential resurgence for rezpeg, previously partnered with Eli Lilly, and may reenergize Nektar's dermatology portfolio.